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Parkinson’s disease and α-synuclein 
 
Parkinson’s disease (PD) is the second most 
common neurodegenerative disorder after Alz-
heimer’s disease, affecting almost 1% of the 
population over 50 years old. Clinical features 
of the disease include bradykinesia, resting 
tremor, muscle tone rigidity, and possible cogni-
tive involvement [1, 2]. Pathologically, PD is 
characterized by selective degeneration of 
dopaminergic neurons in the substantia nigra 
pars compact (SNpc) and the presence of Lewy 
bodies (LBs), primarily composed of fibrillar α-
synuclein (α-Syn) and ubiquitinated proteins, in 
the surviving neurons [3, 4]. 
 
Although more than 90% of PD cases occur spo-
radically, the discovery of monogenic heredi-
table forms of the disease has provided impor-
tant clues as to the understanding of the mo-
lecular mechanisms that lead to neuronal de-
generation in this pathology [5]. Different genes 
have been associated with familial cases of PD, 
including α-Syn, LRRK2, parkin, DJ-1 and PINK1 
[6]. However, the mechanism underlying dis-
ease onset and progression are still unclear. 
Evidences from genetic, pathological and bio-
chemical studies supports critical involvement 
of α-Syn in the pathogenesis of the disease [7, 
8]. 
 
α-Syn is a small natively unfolded protein widely 
expressed in neurons at the presynaptic level 
[9], with a conserved amphipathic N-terminus, 
an acidic C-terminus and a hydrophobic central 
region that is required for both oligomerization 
and fibrillization processes [10]. Although α-Syn 
biological function is still controversial, it has 
been suggested to play a role in synaptic vesi-
cles biogenesis and modulation of synaptic 
transmission [9]. α-Syn (SNCA) gene mutations 
and single-nucleotide polymorphisms (SNPs) 
render α-Syn protein more prone to misfolding 
and accelerate formation of aggregates [5], 
which have been linked to autosomal-dominant 
forms of PD [11] and increased susceptibility to 
sporadic PD [12], respectively. While there is 
clear evidence that α-Syn plays an important 
role in the pathogenesis of PD, it is unclear what 
is/are the toxic form(s) of the protein responsi-
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ble for neuronal dysfunction and the mecha-
nisms by which these purported toxic forms of α
-Syn spreads from neuron to neuron triggering, 
in turn, neuronal degeneration [13]. 
 
Dopaminergic neuronal degeneration 
 
The main pathological hallmark of PD is the 
progressive degeneration and death of dopa-
minergic neurons in the SNpc [14], which leads 
to a severe dopamine depletion in the striatum, 
responsible for the motor symptoms observed 
in the disease [15]. In particular, the SNpc is 
subdivided into ventral and dorsal tiers, and 
neuronal death in PD mainly occurs in the ven-
tral tier; in this regard, studies on post-mortem 
PD brains reported that the degeneration affect-
ing the ventral tier account for 80-95% of neu-
rons loss [16-18]. The pattern of cell loss and 
the selective vulnerability of dopamine (DA) neu-
rons seen in PD do not occur in other neurode-
generative diseases or in normal aging, suggest-
ing that these neurons possess distinct features 
that render them more susceptible to degenera-
tion [19]. Several mechanisms have been pro-
posed to explain the observed vulnerability of 
dopaminergic neurons. First, it was suggested 
that the size and neurochemical phenotype of 
dopaminergic neurons which can make an ele-
vated number of synaptic connections particu-
larly prone to damage can account for the ob-
served vulnerability [20]. Moreover, the large 
amounts of the dark-coloured pigment neuro-
melanin and its ability to interact with transition 
metals, especially iron, and to mediate intracel-
lular oxidative mechanisms has been suggested 
to sensitize this population of cells [21, 22]. In 
addition, an unbalanced DA homeostasis 
(consequent to impaired synthesis, storage, 
degradation and distribution in the synaptic 
vesicles) can lead to increased concentration of 
free cytosolic DA which favors ROS production 
and oxidative stress [19, 23] and, in its oxidized 
form, can itself covalently modify α-Syn and pro-
mote the stabilization of toxic fibrils [24]. Fi-
nally, these neurons exhibit enhanced sensitiv-
ity to pro-inflammatory mediators compared to 
other neuronal populations, likely consequent to 
the high density of microglia cells in this region 
[25]. All these factors have been reported and 
suspected to contribute to the dopaminergic 
neurons vulnerability and degeneration. 
 
Although it is generally accepted that the loss of 
midbrain dopaminergic neurons occurs and is 
largely responsible for the major motor symp-
toms, this is not the only region showing patho-
logical hallmarks in PD patients. Lewy bodies 
and cell loss occur in other non-dopaminergic 
areas of the brain including brainstem cells nu-
clei, olfactory bulb, limbic system and neocortex 
[26, 27] suggesting a mechanism involving 
propagation and progression of the pathology, 
similar to the one observed in prion diseases 
[28]. This model of a pathological propagation 
has recently gained particular attention with 
regard to neurodegenerative diseases linked to 
misfolded and aggregated proteins.  
 
A few years ago, Braak and co-workers [26] pro-
posed a pathological staging process for PD. In 
this system, based on the distribution of α-Syn 
pathology in post-mortem brains, early patho-
logical events first occur in the autonomic nerv-
ous system (stage 0), dorsal motor nucleus of 
the vagus and in the anterior olfactory nucleus 
(stage 1), then spread the locus coeruleus, 
SNpc and basal forebrain (stage 2). In the final 
stages, pathology extends to the neocortex, hip-
pocampus and basal ganglia. Although the 
Braak staging does not fit all disorder associ-
ated with LBs pathology and may be a simplified 
system, it supports the notion that α-Syn deposi-
tions may spread to neighbor cells. There are 
several lines of evidence supporting cell-to-cell 
propagation of α-Syn. First, α-Syn exists as a 
soluble, natively unfolded monomer [29] and/or 
a folded alpha-helix tetramer [30, 31] and, in 
vitro, it can convert into soluble, oligomeric form 
and a beta-sheet, fibrillar form, the latter serv-
ing as seed or template for the formation of 
larger aggregates [32]. Of interest, α-Syn dos-
age is intimately linked to PD, being multiplica-
tions of SNCA cause of hereditable, aggressive 
forms of the disease [33]. Increased cellular 
concentration of α-Syn can be the results of 
impaired protein homeostasis [34]. Accordingly, 
reduced protein clearance due to defects in the 
proteasome and autophagy machineries may 
lead to increased concentration of α-Syn and 
favor the formation of aggregates [35]. In sup-
port of a cell-to-cell propagation α-Syn is the 
striking observation that neural grafts derived 
from midbrain healthy tissue transplanted into 
the striatum of individuals affected with PD 
showed LB pathology after 10-16 years in addi-
tion to the expected Lewy pathology observed in 
the host tissue [36, 37].  
 
It has been shown by independent studies that 
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α-Syn toxic forms can be secreted from cells in 
culture, enter other cells, and seed small intra-
cellular aggregates in the receiving cells [38]. 
Although the precise mechanism is not yet 
clear, it is likely that α-Syn is released by the 
donor cell and uptaken by a recipient cell by 
energy dependent processes. In this regard, 
recent studies have reported the crucial role 
exerted by exosomes as material and structural 
templates transporters from cell-to-cell and as 
potential carriers in the dissemination of PD 
pathology [39, 40]. In the next paragraphs we 
discuss the recent findings on the key role of 
exosomes in the α-Syn spreading from neuron-
to-neuron and in the inflammation propagation 
from immune cell-to-cell, highlighting their po-
tential implication in the propagation and pro-
gression of the PD. 
 
Exosomes biogenesis and physiological 
functions 
 
Exosomes are microvesicles whose biogenesis 
occurs within multivesicular bodies (MVBs) in 
the endosomal system. In details, proteins and 
signaling complexes that are sequestered to the 
limiting membrane of MVBs can be selectively 
incorporated into intraluminal vesicles (ILVs) by 
invagination of the MVB membrane. Here, MVB 
can either fuse with the lysosome membrane to 
degrade ILV and its content, or alternatively with 
the plasma membrane to release the ILV as 
exosomes into the extracellular space [40, 41]. 
 
Exosomes are small vesicles with a size ranging 
from 30 to 120 nm and appear with a charac-
teristic round or cup-shaped morphology as ob-
served by transmission or cryo-electron micros-
copy [42]. These vesicles can be released from 
a variety of cells, both in vitro and in vivo, such 
as neuronal cells including neurons [43], micro-
glia [44], astrocytes [45] and non-neuronal cells 
such as lymphocytes and monocytes [46, 47]. 
Recently, it has been shown that exosomes can 
transport messenger RNA, microRNA, protein 
and signaling complexes, all of which important 
in the modulation of gene and protein expres-
sion in the receiving cells [40, 47]. They contain 
distinct proteins, some are common across all 
exosomes and are used as “marker” protein 
including Alix, tetraspanin (CD63, CD81) and 
heat shock protein (HSP70, 90) [47, 48], while 
others are specific and depend on the cell type 
from which they are secreted [49]. In this re-
gard, it has been reported that exosomes re-
leased from antigen-presenting cells carry the 
major histocompatibility complex (MHC) [50] 
whilst those released from oligondendrocytes 
carry the myelin proteins [51]. 
 
Little is still known about the requirement and 
regulation of exosomes fusion with the plasma 
membrane of secreting and receiving cells. Dif-
ferent studies have suggested that exosomes 
are secreted by a regulated process involving 
the tethering, docking and fusion of the vesicles 
at the plasma membrane probably through a 
specific combination of SNARE proteins, al-
though this combination has not yet been identi-
fied [41, 46]. It has been demonstrated that 
exosomes can be taken up by targeting cells; in 
this regard, different mechanisms have been 
proposed, including endocytosis, receptor-ligand 
binding, attachment or fusion with the plasma 
membrane to deliver their cytosolic content [49, 
52, 53], however the mechanism of interaction 
and secretion has not yet been well established.  
 
Exosomes are biologically active entities and 
are important for a variety of physiological path-
ways. In particular, the fusion of MVB with the 
lysosome results in the degradation of un-
wanted cellular materials, and allows the cell to 
remove transmembrane proteins essential to 
down-regulate activated surface receptors, as 
growth factors or adhesion molecules [54]. 
Moreover, these vesicles have been shown to 
play a functional role in neuronal development 
and regeneration [55], and in the synaptic plas-
ticity of the cortical and hippocampal neurons 
[56]. In addition, when released from immune 
cells, they exhibit immune-stimulatory proper-
ties important to activate and propagate the 
inflammation in response to pathogenic stimuli 
or injury [57, 58]. Recently, in the context of 
pathological processes the role of exosomes 
has been the subject of intensive research, they 
have been implicated in the spread of toxic pro-
teins within the brain and in the progression of 
different neurodegenerative diseases including 
PD [40]. 
 
Exosomes in the cell-to-cell communication and 
their role in the progression of PD 
 
Cell-to-cell communication exerted by exosomes 
in the brain, in particular neuron-to-neuron and 
neuron-to-glia communication, has been in-
tensely studied to investigate their role in the 
progression of the neurodegenerative disease 
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including PD. In this context, it was demon-
strated that α-Syn deposits are released via 
exosomes and in this way are efficiently able to 
transfer and propagate α-Syn toxic forms to 
other cells [40, 59-61]. Different studies dem-
onstrated that α-Syn transferred neuron-to-
neuron is able to form aggregates in recipient 
cells [61, 62]. Moreover, Emmanouilidou and 
colleagues reported that secreted α-Syn via 
exosomes induces cell death of recipient neu-
ronal cells, suggesting that α-Syn deposits 
spreading to the neighbors neurons causes 
propagation of the disease [60]. 
 
Of interest, immunologists started to focus on 
exosomes when they discovered that immune 
cells, B lynmphocytes and dendritic cells, were 
also able to secrete exosomes [57, 63]. Most 
notably, these exosomes when released by den-
dritic cells (DCs) expressed the MHC II bound to 
antigenic peptide, and were able to present 
MHC-peptide complex to T cells promoting their 
activation [46, 57, 58, 64]. In addition, a recent 
study reported that exosomes released from 
infected macrophages expressed pathogen-
associated molecular patterns (PAMPs) and can 
stimulate macrophages activation by pattern 
recognition receptor (PRP), and pro-
inflammatory response both in vitro and in vivo 
[65]. This role of exosomes in antigen-specific 
immune response results in the spread of anti-
gens or MHC-peptide complex between immune 
cells, causing the propagation of inflammatory 
response. Moreover, exosomes can contain pro-
inflammatory mediators such as IL-1β and TNF-
α, which are involved in the modulation and 
propagation of inflammatory response [46, 58]. 
Overall these evidences suggest that exosomes 
could play an active role in the immune re-
sponse, thus contributing to the induction, am-
plification and modulation of inflammatory re-
sponse. 
 
In this regard, several studies have reported 
that α-Syn deposits released from neurons can 
be endocytosed by astrocytes and microglia, the 
brain immune cells, probably in an attempt to 
clear toxic species of the protein [41, 66, 67]. 
However, excessive α-Syn uptake in these cells 
could produce glia inclusions, similar to the 
ones found in PD brains [68], and trigger inflam-
matory response [67, 69]. Indeed, it has been 
reported that α-Syn released by injured neurons 
is able to induce and maintain inflammatory 
response through activation of microglia cells 
[8, 70].  
 
Inflammation is sustained by multiple interac-
tions among cells, and in this context exosomes 
might act at different stages of the process, 
including the activation level, through neuron-to-
glia communication, or during the propagation 
of the inflammatory response through glia-to-
glia communication, as depicted in Figure 1. To 
date, it has been widely investigated and dis-
cussed the pathogenic transmission of α-Syn-
derived exosomes between neuron-to-neuron 
and neuron-to-glia cells, however studies on the 
role of exosomes in glia-to-glia communications 
and their potential impact in the progression of 
PD and other neurodegenerative diseases are 
missing. Although a well-regulated inflammatory 
process is essential for tissue repair, an exces-
sive or protracted inflammatory response can 
result in a more severe and chronic neuroin-
flammatory cycle that promotes the progression 
of the disease [71]. In fact, it is now established 
that inflammation is a key hallmark of PD patho-
genesis and can contribute and exacerbate the 
nigral neurodegeneration observed in the dis-
ease [72].  
 
Notwithstanding it is established that exosomes 
are involved in the pathogenesis of neurodegen-
erative diseases, we are still required to investi-
gate the molecular pathways that regulate their 
assembly, secretion, interaction with receiving 
cells and the stimuli that trigger their release 
both in vitro and in vivo. Increasing our knowl-
edge on the cell-to-cell transmission of α-Syn 
toxic forms and of inflammatory mediators be-
tween brain cells, might provide new insights 
into mechanism of disease onset and progres-
sion and identify novel strategies for diagnosis 
and therapeutic intervention in PD and other 
neurodegenerative diseases. 
 
A role of PD related genes in exosome secre-
tion? 
 
As discussed earlier, exosomes derive from 
MVBs that can either fuse with the lysosome for 
degradation and with the plasma membrane for 
exosome release to the extracellular space. A 
number of genes linked to PD, either carrying 
causal mutations (LRRK2, ATP13A2 and VPS35) 
or more common variants acting as risk factors 
(heterozygous mutations in GBA), have been 
suggested to play a role in lysosomal-
endosomal pathways. In particular, recent stud-
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ies have provided strong evidence that LRRK2 
directly impacts the secretory and endocytic 
machinery. Shin and colleagues [73] demon-
strated that LRRK2 interacts with Rab5b, a 
regulator of endocytic vesicle trafficking. In addi-
tion, LRRK2 has been observed to modulate 
synaptic vesicle trafficking via interaction with 
pre-synaptic proteins such as NSF, actin, syn-
taxin and SV2A [74]. Xiong and colleagues over-
expressed wild type LRRK2 in primary neuronal 
cultures and documented reduced rates of syn-
aptic vesicle endocytosis and exocytosis in hip-
pocampal neurons [75]. Interestingly, LRRK2 
has been found to co-localize with MVBs [76]. 
Although a role for LRRK2 in exosome secretion 
has not been described yet, based on the strong 
links between LRRK2 function and endosome-
lysosome related pathways, we can speculate 
that LRRK2 activity is important in exosome 
secretion during fusion of MVBs with the plasma 
membrane. In particular, LRRK2 may function 
as scaffold to assemble components of the fu-
sion machinery such as its partner NSF [74], 
which has been shown to participate in the fu-
sion between MVBs with the plasma membrane 
to release exosomes into the extracellular space 
[77]. In addition, Alegre-Abarrategui and col-
leagues [76] observed that R1441C LRRK2 
pathological mutation induce the formation of 
skein-like abnormal MVBs. One possibility is 
that abnormally large MVBs due to pathological 
LRRK2 activity contain and release an in-
creased number of exosomes, and, as conse-
quence, more α-Syn toxic forms are present in 
the extracellular space leading thus to the 
spread of the disease. 
Figure 1. Exosomes in the cell-to-cell communications and their role in the progression of PD. Exosomes containing α-
Syn released by injured neurons can be transmitted from neuron-to-neuron thus leading to α-Syn spreading, and from 
neuron-to-glia leading to activation of inflammatory response. In turn, exosomes released by activated glial cells, con-
taining inflammatory mediators, can be transmitted from glia-to-glia leading to the propagation of inflammatory re-
sponse. Consecutively, the propagation of inflammatory mediators and the exacerbated neuroinflammation could 
contribute to neuronal dysfunctions and to progression of the disease.  
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It has been reported that variation in tau gene 
(MAPT), which encoding for a protein involved in 
the pathogenesis of Alzheimer’s disease [78], 
can confer genetic risk for PD [79, 80]. In this 
regard, an interesting study reported that under 
pathological conditions tau protein can interact 
with α-Syn promoting the oligomerization and 
the toxicity of these proteins [81]. Taken to-
gether these data suggest that tau can acceler-
ate the exosomes-mediated release containing 
α-Syn toxic forms from injured neurons. 
 
Of interest, Vacuolar Sorting Protein 35 
(VPS35), a protein that mutated is cause of late-
onset autosomal dominant PD, is an essential 
component of the retromere complex, which 
performs the retrograde transport from the en-
dosome to the Golgi apparatus. Sullivan et al. 
[82] observed that cells with defective retro-
mere activity displayed increased exosomal se-
cretion of amyloid precursor protein (APP). Al-
though experimental models are not yet avail-
able, we can predict that pathological mutations 
of VPS35 may lead to aberrant exosome secre-
tion with consequent accumulation of extracel-
lular α-Syn and cell-to-cell propagation of the 
pathology. Establishing whether LRRK2, tau, 
and VPS35 operate within the exosome path-
way might provide important clues on the patho-
logical mechanisms of α-Syn spreading and pro-
gression of the disease. 
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